by As soon as the news spread regarding Covid 19, doctors and scientists started working towards making a Vaccine and after a lot of patience, hard work and tests, India became the first nation to prepare not just one but two successful vaccines to fight against the Virus. One is from Bharat Biotech, based in Hyderabad whereas other is from Serum Institute of India (SII)
Now, with 2 different vaccines that are ready to be used, a controversy has taken a rise.
Here is a brief comparison between both the vaccines that as an Indian citizen we all must know about:
SII VACCINE Vs. BHARAT COVID VACCINE
Regarding Covaxin from Bharat Biotech, regulatory stated that it has been approved for restricted use in emergency situations in public interest as an abundant precaution in clinical trial mode. In this case, some experts wonder how and why a vaccine that is still under its trial was cleared for emergency use by millions of people.
Bharat Biotech in this case has revealed that Indian Clinical trial laws allowed accelerated authorization for use of drugs after the second phase of trials for unmet medical needs of serious diseases in the country and has also promised to provide efficacy data till February.
Regarding Covishiled that is produced by SII is made from a weakened version of a common cold virus from Chimpanzees that has been modified to look like a Corona Virus. When Covishield is injected, it prompts the immune system and makes antibodies that attack the virus infection. 2 doses are to be given between 4 to 12 weeks apart.
SII in this controversy stated that Covishield is highly effective that is backed by Phase 3 trial data from United Kingdom and Brazil but All India Drug Action Network says that its approval has been rushed because the bridging study of the vaccine on Indians is yet to be completed. Answering to this, SII has promised to conduct the bridging trial in India in February.
The Covishield vaccine’s first dose has already been shared with Bangladesh, Nepal, Bhutan, Seychelles, Myanmar and Maldives. Astra –Zeneca has an agreement for 1 billion doses.
